VIP (Vasoactive Intestinal Peptide)ImmuneSafety Rating 6/10
Primary research areaCIRS (Chronic Inflammatory Response Syndrome)
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Research dose range50 mcg intranasal 4x/day (Shoemaker protocol for CIRS). SC dosing also used. Cycle individualized.
AdministrationInjection / Intranasal
Safety6/10 · Not FDA-approved
NCAA D1Not listed
Price Comparison
Compare vendors · per 10mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| PureRawzBest $/mgCOA ✓ · 3P | $42.48 | $3.54 | May 14, 2026 | Buy → |
| Ascension PeptidesCOA ✓ · 3P | $47.00 | $4.70 | Apr 16, 2026 | Buy → |
| Puratek PeptidesCOA ✓ · 3P | $48.56 | $4.86 | May 19, 2026 | Buy → |
| Behemoth LabzCOA ✓ · 3P | $77.39 | $7.74 | May 14, 2026 | Buy → |
| Behemoth LabzCOA ✓ · 3P | $94.22 | $7.85 | May 14, 2026 | Buy → |
Overview
About VIP
Mechanism of action
Neuropeptide that binds VPAC1/VPAC2 receptors; vasodilator; bronchodilator; potent anti-inflammatory; modulates immune function; regulates circadian rhythms and neurotransmission.
Safety profile
Flushing, headache, nausea, hypotension (especially IV). Intranasal generally well-tolerated. · Endogenous neuropeptide; clinical use for pulmonary conditions; vasodilation, diarrhea; tolerable
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops VIP below your target.
Related pages